Phase 1 N=19 Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 1; 2; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Understanding Dexmedetomidine in Neonates After Open Heart Surgery
Tetrology of Fallot · Heart Ventricle · Hypoplastic Left Heart
Primary: PK Profile of Dexmedetomidine — 110 mL/min
Phase 1 N=92 Interventions of Smoking Cessation During Pregnancy
Smoking Cessation
Primary: Participants' Smoking Status — 253.6; 678.9; 311.9; 479.6 ng/ml
Phase 1 N=56 Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery
Hypoplastic Left Heart · Tetralogy of Fallot · Tricuspid Atresia
Primary: PK Profile of Dexmedetomidine — 28 mL/min/(kg^0.75)
Phase 1 N=11 Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Breast Cancer
Primary: The Number of Participants Who Experienced Dose-limiting Adverse Events — 1; 0 participants
Phase 1 N=12 Ph1 Marinol Interaction Study - Part 2 - 1
Marijuana Dependence
Primary: Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects. — 6; 6 participants
Phase 1 N=50 Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Heart Failure
Primary: The Number of Participants Reporting Adverse Events (AEs) — 0; 0; 3; 0 Participants
Phase 1 N=36 A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Alzheimer's Disease · Huntington's Disease
Primary: Balance of Effects- Drug Liking VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin) — 57.8; 78.6; 82.2; 57.2 mm — p=<0.0001
Phase 1 N=230 Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)
Fungal Infections
Primary: Average Concentration (Cavg) of Posaconazole Tablet — 981; 1580 ng/mL
Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Phase 1 N=48 Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants
Pharmacokinetics and Pharmacodynamics
Primary: Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter — 55.28; 114.08; 246.00; NA ng/mL
Phase 1 N=46 A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors
Neoplasm
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Phase 1 N=200 Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
Influenza
Primary: Number of Subjects With Solicited Local Symptoms. — 48; 48; 1; 0 subjects
Phase 1 N=21 A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
Hepatitis C Virus
Primary: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Methadone Enantiomers When Administered With or Without Boceprevir — 50.1; 42.4; 56.9; 44.6…
Phase 1 N=44 Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients
Adult Stem Cell Hematopoetic Transplant
Primary: Patients Experiencing at Least 1 Solicited Local and/or Systemic Adverse Event After High Dose (HD) Trivalent Influenza Vaccine (TIV) or Standard Dose (SD) Trivalent…